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Summary Objectives: To evaluate the value of plasma ﬁbronectin (pFN) as a diag-
nostic marker of sepsis.
Subjects andmethods: Plasma FNwas determined in patients showing sepsis-related
symptoms who had blood cultures performed. These patients were assigned to one
of two groups according to their clinical situation: (1) Clinical Septic Group: patients
with sepsis according to American College of Chest Physicians/Society of Critical Care
Medicine (ACCP/SCCM) criteria; (2) Fever Peak Group: patients who did not fulﬁl suf-
ﬁcient ACCP/SCCM criteria for sepsis. Two additional control groups were also estab-
lished: (3) Non-infectious Diseases Control Group and (4) Healthy Control Group.
Results: Plasma FN levels, microbiological and clinical data were compared among
the different patient groups. For each group, the number of patients, median and
mean pFN levels and the 95% conﬁdence interval of the mean were: (1) n = 43,
102mg/l, 122mg/l (100—144); (2) n = 70, 185mg/l, 207mg/l (184—231); (3) n = 22,
175mg/l, 181mg/l (151—211); and (4) n = 22, 256mg/l, 261mg/l (229—292).
Bonferroni’s test of multiple comparisons was able to detect a signiﬁcant differ-
ence between pFN concentrations corresponding to the septic group, compared to
the remaining groups (pANOVA < 0.001).
Conclusion: Plasma FN appears to act as a marker of sepsis in that patients showed
diminished pFN levels. Along with other clinical and laboratory variables, the use of
this marker would allow a rapid diagnosis of sepsis and limit the number of blood cul-
tures to be processed and the number of antibiotic prescriptions, particularly when
symptoms are insidious and diagnosis is doubtful. We propose further and more com-
plex studies using a higher number of patients.
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rights reserved.
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Introduction
Sepsis is a common disease that shows increas-
ing morbidity and mortality, particularly in el-
derly, immunosuppressed or critically ill patients.
The diagnosis of sepsis is easy when it presents
as abrupt fever, shivers, tachycardia, tachypnea,
acute change in mental state or hypotension and
the source of infection is known. However, at times
the initial symptoms are insidious and similar to
those of other diseases that are not, in principal,
related to the infection, such as trauma, burns,
chemical pancreatitis, etc.
In the early 1990s, the American College of
Chest Physicians/Society of Critical Care Medicine
(ACCP/SCCM) established a set of consensus crite-
ria for the diagnosis of clinical sepsis1—3 with the
goal of standardising terminology and improving
the homogeneity of patient populations in clinical
studies.
The clinical symptoms of sepsis are the re-
sult of interaction between bacterial products
and host mediating systems such as the cytokine
cascade,4—10 vasoactive peptides, products of
arachidonic acid metabolism and acute phase
reactants.11 A signiﬁcant challenge is to progress
from diagnosing clinical syndromes to identifying
more speciﬁc entities deﬁned by alterations in
speciﬁc immunologic or biochemical pathways.
The value of circulating endotoxin and media-
tors including various pro- and anti-inﬂammatory
cytokines in predicting clinical outcome has been
explored in diverse groups of critically ill patients,
with variable results.12—18
Soluble plasma ﬁbronectin (pFN) is a high molec-
ular weight protein whose principal functions are
related to the host response to infection.9—29 Sev-
eral effects in the pathogenesis of sepsis have been
proposed for pFN:
• It interacts with phagocytes at nearly every stage
of the inﬂammatory response to infection.19
• It acts in conjunctionwith the reticulo-endothelial
system in the removal of collagen remnants,
damaged platelets and necrotic tissue.20
• It plays a role in maintaining vascular integrity
and in wound recovery, triggering the blood clot-
ting process.30
• It acts as a modulator in the complement system,
stimulating its bactericidal capacity.19
No congenital pFN defects have been described,
only acquired situations in which pFN concentra-
tions are abnormally diminished such as in the case
of disseminated intravascular coagulation and cry-
oﬁbrinogenaemia, due probably to increased pFN
catabolism secondary to the intravascular forma-
tion of ﬁbrin. There are also situations in which
pFN can be abnormally high, such as occurs in
nephritic syndrome and cholestasis, independent
of the aetiology,21 due to defects in its removal
(retrograde circulation) or to enhanced synthesis
because of the stress to which the hepatocyte is
subjected. Sex and age are unassociated with the
concentration of pFN.21
The aim of this study was to evaluate the poten-
tial value of pFN as a diagnostic marker for sepsis
in clinical practice by comparing pFN levels in clin-
ically septic patients and control patients in terms
of clinical and microbiological diagnostic criteria.
Patients and methods
Study design
A prospective transverse study was designed and
performed at the Segovia General Hospital (a
350-bed secondary care hospital). Over a six month
period, all requests for blood cultures made to
the microbiology laboratory of the hospital were
accompanied by a heparinised blood sample for
pFN determination. All clinical and microbiolog-
ical data for the period were recorded. Blood
cultures were processed in a BACTEC NR 660 sys-
tem (Becton—Dickinson) and other sample cul-
tures were performed using routine methods at
the hospital microbiology laboratory. Plasma FN
was determined at the microbiology department
of the Faculty of Medicine, Complutense Univer-
sity of Madrid using a Behring N100 nephelometer.
The lower detection limit of this instrument was
80mg/l. For statistical purposes, pFN levels under
detection limits were recorded as 80mg/l.
Patient selection and classiﬁcation
All patients for whom a blood culture was requested
were assigned to one of two groups according to
their clinical situation:
• Clinical Septic Group (CSG): patients submitted
for blood culture who fulﬁlled ACCP/SCCM cri-
teria for sepsis,1 i.e., patients with systemic in-
ﬂammatory response syndrome (SIRS) and a sus-
pected infectious aetiology, independent of the
severity of sepsis.
• Fever Peak Group (FPG): patients submitted for
blood culture but who did not meet sufﬁcient
ACCP/SCCM criteria. These patients generally
presented a temperature peak.
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In these two groups, plasma samples for FN deter-
mination were aliquoted and frozen (−50 ◦C) at the
time of onset of symptoms along with three serial
blood cultures performed at 30minute intervals.
Two additional control groups were also estab-
lished:
• Non-Infectious Diseases Control Group (NIDCG):
patients admitted to the Internal Medicine De-
partment with diseases of a non-infectious aetiol-
ogy such as acute myocardial infarction, cardiac
insufﬁciency, bleeding from the proximal diges-
tive tract, acute cerebrovascular accident, res-
piratory insufﬁciency, pancreatitis, etc.
• Healthy Control Group (HCG): volunteers from
the staff of the Segovia General Hospital.
Statistical analysis
The null hypothesis proposed was that ‘there is no
difference in pFN levels between the septic and the
other groups’.
Plasma FN levels were compared among groups
through one factor ANOVA and signiﬁcance cor-
rected using the Bonferroni test. The null hypoth-
esis was rejected in each test when the error
α < 0.05. Results are expressed as the mean, me-
dian, standard error and 95% conﬁdence interval of
the mean.
The distribution frequencies of the qualitative
variables were compared using Chi-squared or
Fisher’s exact tests. Statistical analysis was per-
formed using SPSS v.8.0 software.
The following validity indices were calculated:
sensitivity, speciﬁcity, positive predictive value
(PPV), negative predictive value (NPV), diagnos-
tic efﬁciency for different pFN concentrations and
the receiving operating curve (ROC), considering
patients with positive cultures as having a real
diagnosis of sepsis with respect to the non-septic
subjects (HCG and NIDCG).
Results
Clinical Septic Group
Clinical Septic Group: n = 43, 28 male/15 female,
mean age 66 years. In most cases, only two or three
SIRS inclusion criteria were fulﬁlled at the onset
of the sepsis episode. Fever was the most common
symptom (93%) followed by leukocytosis (67%) and
tachycardia (65%).
The hospital units harbouring the largest number
of cases were: internal medicine with 13 patients
(30%), intensive care unit eight patients (19%),
haematology seven patients (16%) and surgery six
patients (14%). Underlying diseases such as neopla-
sia, leukaemia, chronic pulmonary obstructive dis-
ease, insulin-dependent diabetes mellitus, chronic
renal insufﬁciency, etc. were recorded in 23 of the
patients with sepsis (54%).
According to ACCP/SCCM1 classiﬁcation criteria,
we found 19 patients (44%) with sepsis, and 16 (37%)
with severe sepsis (SS). Eight further cases (19%)
were graded as septic shock or multiple-organ dys-
function syndrome (MODS).
Thirty-seven patients (86%) were discharged and
six (14%) died because of complications related to
the septic process.
In 27 patients (63%), microbiological cultures
were positive, conﬁrming that the greater the
severity of sepsis the more efﬁcient the culture.
Of these, ten corresponded to patients with sepsis
(53% of all cases of sepsis), ten with SS (63% of all
cases of SS) and seven with MODS (88% of all MODS
cases).
The most frequent site of infection was the res-
piratory tract, with a microbial isolation rate of
62%. In patients where the infection site was the
gastro-intestinal tract, cultures were positive in
92%, with a predominance of enterobacteria. When
the main site of infection was the urino-genital
tract, 71% yielded positive cultures, comprising
mainly enterobacteria. In a further subgroup of pa-
tients with fever of unknown origin, cultures were
positive in only 14% of cases (Table 1). Other sites
of infection, such as catheters or skin, were asso-
ciated with a 50% positive culture rate. In all but
one of the patients who died, microorganisms were
isolated.
The mean pFN for the CSG was 122mg/l (95% CI
100—144). The median and 75th percentile (p75)
were 102 and 118mg/l respectively. A high propor-
tion of the blood samples in this group showed un-
detectable pFN levels (35%).
From an aetiological perspective, there was no
signiﬁcant difference in pFN concentration in the
CSG related to the culture results: negative cul-
ture, isolation of Gram-negative or Gram-positive
microorganisms.
There were no signiﬁcant differences in pFN
among groups according to the severity or source
of infection. Even the fever of unknown origin sub-
group showed a mean pFN value as low as that
recorded in patients where the source of infection
was known (Table 1).
Fever Peak Group
Fever Peak Group: n = 70, 46 male/24 female,
mean age 62 years. The mean pFN for this group
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was 207mg/l (95% CI 184—231). The median and
p75 were 185 and 264mg/l.
It was possible to isolate microorganisms in ten
FPG patients. The mean pFN level estimated for
this small subgroup (FPsG) was 141mg/l (95% CI
93—189); very similar to values for the CSG.
Non-Infectious Diseases Control Group
Non-Infectious Diseases Control Group: n = 22, 12
male/10 female, mean age 60 years. The mean pFN
for this group was 181mg/l (IC95% 151—211). The
median and p75 were 175 and 233mg/l.
Non-Infectious Diseases Control Group
Healthy Control Group: n = 22, 9 male/13 female,
mean age 32 years. The mean pFN for this group
was 261mg/l (95% CI 229—292). The median and
p75 were 256 and 318mg/l.
A complete statistical description of the study
and control groups is presented in Table 2.
Figure 1 shows mean pFN concentrations with
the corresponding error bars and 95% CI for each
group. Bonferroni’s test of multiple comparisons
was able to detect a signiﬁcant difference between
pFN levels corresponding to the CSG and the re-
maining groups (pANOVA < 0.001), but not the FPsG.
No signiﬁcant differences were shown between
FPG vs NIDCG nor FPG vs HCG.
It is of interest that the mean pFN concentra-
tion corresponding to the 37 positive culture pa-
tients (27 in CSG and ten in FPsG) was 136mg/l (95%
CI 108—163). The median and p75 were 105 and
150mg/l respectively. A high proportion of blood
samples showed undetectable pFN levels (30%). In
addition, we found two abnormally high pFN deter-
minations in two bacteraemic patients.
Sensitivity, speciﬁcity, positive predictive value,
negative predictive value and efﬁciency of pFN in
culture-positive patients (37 subjects) with respect
to NIDCG and HCG (22 subjects each group) using
different cut-off values are provided in Table 3.
Figure 2 shows the diagnostic efﬁciency curve (ROC)
with an Area Under the Curve value of 0.81 (95%CI
0.71—0.91) p < 0.001.
Discussion
Sepsis is a clinical entity that is sometimes very
difﬁcult to diagnose. In clinical practice, it is very
common for hospital patients to develop all or
some SIRS symptoms with no apparent source of
infection, as occurs in fever of unknown origin or
in immunosuppressed patients. In these cases, the
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Table 2 Descriptive statistics of the study groups.
Clinical Septic
Group
Fever Peak
Group
Non-Infectious Diseases
Control Group
Healthy Control
Group
Population size (n) 43 70 22 22
Mean pFN (mg/l) 122 207a 181b 261a
Standard error 11.1 11.6 14.4 15.1
95% CI (mg/l) of mean 100—144 184—231 151—211 229—292
Maximum pFN (mg/l) 414 498 346 390
Minimum pFN (mg/l) 80 80 80 135
50th percentile (median) 102 185 175 256
75th percentile 118 264 233 318
Undetectable pFN (%) 35 7c 9c 0c
pFN: Plasma ﬁbronectin; CI: Conﬁdence interval.
a p < 0.005 (Bonferoni with respect to the Clinical Septic Group).
b p < 0.05 (Bonferroni with respect to the Clinical Septic Group).
c p < 0.005 (Chi-squared with respect to the Clinical Septic Group).
clinician is faced with the dilemma of whether to
initiate antibiotic treatment or not.
Microbiological cultures have ceased to be a re-
quirement for the diagnosis of sepsis due to the
high number of false negatives produced and the
fact that results take at least 24—48 hours. It is es-
timated that bacteraemia may be culture-proven in
as few as 45—48% of septic patients31 and that in one
in seven cases, all the cultures performed through-
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Figure 1 Mean plasma ﬁbronectin concentration in the septic and control groups showing error bars and 95% conﬁ-
dence intervals. HCG: healthy control group; FPG: Fever Peak Group; NIDCG: Non-Infectious Diseases Control Group;
CSG: Clinical Septic Group. ns: p > 0.05; ∗p < 0.05; ∗∗p < 0.005. Bonferroni’s test of multiple comparisons was able
to detect a signiﬁcant difference between data corresponding to the CSG and the remaining groups (pANOVA < 0.001).
No signiﬁcant differences were shown by FPG vs NIDCG nor FPG vs HCG.
out the sepsis episode prove negative. This difﬁ-
culty in diagnosis has led to the indiscriminate use
of antibiotics with the widely applied management
strategy of ‘treat ﬁrst and look at the test results
later’. This approach has the drawback of contribut-
ing towards increasedmicroorganism resistance and
representing an enormous cost to public health.
Current techniques such polymerase chain reaction
(PCR) have not yet been adopted by clinical labora-
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Table 3 Validity indices of plasma ﬁbronectin (pFN) concentration as a diagnostic test.
pFN cut-off value (mg/l) Sensitivity (%) Speciﬁcity (%) PPVa (%) NPVb (%) Efﬁciency (%)
110 62.2 93.2 88.5 74.5 81.0
120 64.9 88.6 82.8 75.0 77.8
130 64.9 86.4 80.0 74.5 76.5
140 73.0 81.8 77.1 78.3 77.8
150 75.7 81.8 77.8 80.0 79.0
160 78.4 77.3 74.4 81.0 77.8
a Positive predictive value.
b Negative predictive value.
tories due to their complexity and high costs. It is
likely that in the future, the accurate diagnosis of
sepsis will involve the use of genetic biochips.
This lack of speciﬁc clinical criteria and sensi-
tive, rapid microbiological tests has meant that
for several decades a subject of research has been
the role, as an early marker for sepsis, of a mul-
titude of immunoregulatory factors involved in
the body’s systemic inﬂammatory response to an
external infectious agent. Although several au-
thors have approached this objective with more or
less optimistic results,4—18 when these are com-
pared there appear to be discrepancies. This may
be explained by the different criteria employed
for the recruitment of patients and study designs
that establish highly different objectives; in some
cases early diagnosis is considered and in oth-
ers the risk of mortality is taken as the outcome
measure.
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Figure 2 Receiving operating curve (ROC) for plasma
ﬁbronectin levels. AUC = 0.81 (95%CI 0.71—0.91);
p < 0.001.
Over several decades, reduced pFN levels have
been associated with sepsis21—29 to the extent
that several authors have evaluated the effects of
treatment with FN concentrates.32—34 According
to Stathakis et al.,21 sex and age are not associ-
ated with the concentration of pFN, thus the lack
of parity between the septic and control subjects
is not considered to affect the results discussed
here. There are some situations, such as in cry-
oﬁbrinogenaemia or intravascular disseminated
coagulation, in which pFN can be abnormally low,
possibly due to enhanced catabolism of the protein
secondary to intravascular ﬁbrin formation. Very
high pFN levels may also be found due to defects
in its removal (retrograde circulation) or due to
enhanced synthesis because of the stress to which
the hepatocyte is subjected (as occurs in cholesta-
sis) independent of the aetiology,21,35 or to di-
minished catabolism in hyperﬁbrinogenaemia. This
could explain the high pFN levels found in the two
bacteraemic patients with cholestasis and hyper-
ﬁbrinogenaemia (376 and 414mg/l, respectively).
Of the 113 patients in this study, for whom the
physician requested blood cultures and prescribed
antibiotic treatment, only 43 fulﬁlled ACCP/SCCM
clinical criteria of sepsis, and microorganisms could
only be isolated in 37, ten of whom met insufﬁcient
clinical criteria for sepsis to be diagnosed.
The statistically signiﬁcant difference in mean
pFN levels observed between the CSG and remain-
ing groups (pANOVA < 0.001) conﬁrms that pFN be-
haves as a negative acute phase reactant, showing
low values in septic patients compared to healthy
subjects and patients with different non-infectious
pathologies.
The lowmean andmedian pFN values and the high
proportion of plasma samples showing undetectable
levels of pFN (30%) recorded in the CSG compared
to the other groups also suggest the possible use of
pFN as a marker of sepsis.
The ﬁnding of extremely high pFN values in two
culture-proven septic patients affects the statisti-
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cal analysis. Despite this, 75% of the CSG patients
showed a pFN level under 118mg/l.
The reduced pFN concentration was not associ-
ated with the severity of infection, type of microor-
ganism or source of infection (Table 1). As previ-
ously reported,29 perhaps the time course of pFN
levels would be useful to reﬂect the severity of in-
fection and monitor the clinical course of septic pa-
tients.
The fact that subjects in the FPG and NIDCG
showed intermediate pFN levels, under those of
the HCG and above levels recorded in the CSG,
might be explained by the constant reparatory
action exerted by pFN. When it is slowly con-
sumed, it is constantly replaced via hepatic syn-
thesis and release by insoluble FN on the sur-
face of most of the organism’s cells, particularly
ﬁbroblasts.
The need for objective and reliable variables that
may be easily and rapidly measured to conﬁrm diag-
noses and aid therapeutic management along with
the development of complex computer systems ca-
pable of processing large datasets, has led to the
design of speciﬁc scoring systems for sepsis diagno-
sis based on a multitude of both clinical and labo-
ratory variables.
The present ﬁndings suggest that pFN would
act as an early marker of sepsis because when a
septic process is suspected, even before the full
development of clinical signs of SIRS, as seen here
in patients with positive microbiological culture
results who did not fulﬁl the clinical criteria of
sepsis, or when there is no clinical evidence of
the source of infection (irrespective of severity),
a pFN concentration under 120mg/l could suggest
a diagnosis of sepsis (PPV 82.8%). If, on the con-
trary, the pFN concentration is above 150mg/l,
this would appear to rule out a diagnosis of sepsis
(NPV 80.0%).
However, we propose complementary and more
complex studies aimed at designing a speciﬁc
scoring system for the diagnosis of sepsis includ-
ing several easily determined clinical variables
in addition to laboratory variables such as pFN
levels, C-reactive protein, procalcitonin, serum
lactate, etc. Such a scoring system could help
physicians reduce the number of blood cultures
to be processed and the number of antibiotic
prescriptions.
Although the gold standard is yet to be discov-
ered, the reticence towards introducing cellular,
humoral and molecular methods in clinical and lab-
oratory practice should be overcome. These ap-
proaches will no doubt serve to apply biological
knowledge on basic host-microorganism relation-
ships acquired over the past decades.
Conclusions
Based on both the results of this study and others,
where pFN appears to act as a marker of sepsis,
determinations of pFN level, together with other
clinical and speciﬁc immunologic or biochemical
markers easily determined in emergency laborato-
ries, would aid in the rapid diagnosis of sepsis. This
would be particularly useful when symptoms are
insidious and diagnosis is doubtful.
These ﬁndings prompt the need for more complex
studies performed on larger patient series.
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